Article Text

PDF
CP-152 Effectiveness and safety of brentuximab in hodgkin’s and non-hodgkin’s lymphoma
  1. M Sáez Belló,
  2. B Porta Oltra,
  3. M Climente Martí
  1. Hospital Universitario Dr. Peset, Pharmacy, Valencia, Spain

Abstract

Background Brentuximab vedotin (SGN-35) is a treatment option for patients with relapsed or refractory Hodgkin’s lymphoma (HL) and systemic anaplastic large-cell lymphoma (ALCL), with only two phase II studies.

Purpose To evaluate the effectiveness and safety of SGN-35 in patients with relapsed or refractory HL and ALCL.

Material and methods Type of study: retrospective observational cohort study.

Inclusion criteria: patients with relapsed or refractory HL and ALCL, treated with SGN-35 in monotherapy from 05/2012 to 09/2014.

Variables: age, sex, type of lymphoma, stage and International Prognostic Index (IPI score); number of prior courses of chemotherapy, autologous stem-cell transplantation (auto-SCT) and clinical response to prior treatment; number of cycles, dose reductions, clinical response according to the Revised Response Criteria for Malignant Lymphoma: complete remission (CR), partial remission (PR), stable disease (SD) and progressed disease (PD). Incidence and severity of side effects (CTCAE v4.03 criteria).

Results We included 5 patients (3 women, 2 men) aged 47 (30; 52) years. 4 patients suffered from HL, stages II-A, II-B, III-A, IV-B, and 1 ALCL stage IV-A. The IPI score was: III 2 patients, IV 1 patient (2 patients not specified).

Our patients had received 2 (2; 4) chemotherapy cycles before SGN-35 and 3 of them had undergone an auto-SCT. Clinical response to prior therapy was CR in 2 and PR in 3 patients.

After 4 (2; 16) cycles (1 patient with a 17% reduction of dose because of his previous hepatic impairment) 2 patients achieved CR, 1 PR and 1 PD. At the end of the follow-up period, 3 patients carried on with the treatment (1 without evaluation of the response) and 2 patients had died (1 CR and 1 PD) with a time to progression of 2.5 (2; 3) months.

  1. 1 patient suffered from side effects: facial rash and a post-infusion reaction grades I-II.

Conclusion In our population 3 of 5 patients treated with SGN-35 achieved an objective response for 2.5 months, with favourable safety profile.

References and/or Acknowledgements

  1. JCO30 (18):2190–6

  2. JCO30 (18):2183–9

References and/or AcknowledgementsNo conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.